Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

TEST:
therascreen® FGFR RGQ RT-PCR Kit

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Type:

FDA Approved

Related tests:

‹

therascreen® EGFR RGQ PCR Kit (5)

therascreen® KRAS RGQ PCR Kit (5)

therascreen® PIK3CA RGQ PCR Kit (3)

therascreen® BRAF V600E RGQ PCR (2)

Ipsogen JAK2 RGQ PCR Kit

ipsogen BCR-ABL1 mbcr Kit

ipsogen JAK2 MutaScreen Kit

therascreen PDGFRA RGQ PCR kit

therascreen® EGFR Plus RGQ PCR Kit

therascreen® EGFR RGQ PCR Kit (5)

therascreen® KRAS RGQ PCR Kit (5)

therascreen® PIK3CA RGQ PCR Kit (3)

therascreen® BRAF V600E RGQ PCR (2)

Ipsogen JAK2 RGQ PCR Kit

ipsogen BCR-ABL1 mbcr Kit

ipsogen JAK2 MutaScreen Kit

therascreen PDGFRA RGQ PCR kit

therascreen® EGFR Plus RGQ PCR Kit

›

Evidence Level:

Sensitive: A1 - Approval

[FGFR3 mutation-Urothelial Cancer-erdafitinib]

Source:

Test:

therascreen® FGFR RGQ RT-PCR Kit

Excerpt:

BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has...susceptible FGFR3 or FGFR2 genetic alterations and...progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Evidence Level:

Sensitive: A1 - Approval

[FGFR2 mutation-Urothelial Cancer-erdafitinib]

Source:

Test:

therascreen® FGFR RGQ RT-PCR Kit

Excerpt:

BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has...susceptible FGFR3 or FGFR2 genetic alterations and...progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.